Understanding the factors that cause people to transition from normal aging to preclinical Alzheimer's disease (AD) to mild cognitive impairment, and subsequently convert to dementia is the central focus of the University of California Alzheimer's Disease Research Center (UCI ADRC). The UCI ADRC integrates basic and translational science and clinical domains to elucidate the heterogeneity in the clinical sub-types of AD, including early-onset, genetic, and late-onset forms. As such, we follow three valuable cohorts: (1) longitudinal cohort, which includes older adults with preclinical and early-stage AD, (2) Down syndrome cohort, representing the largest genetically at-risk population for AD, which enables us to describe the role of amyloid deposition in the early years of the life span and the particular vulnerability that this might impart for developing AD, and (3) the oldest-old, as part of the 90+ Autopsy Study, which show great disparity between AD pathology and cognitive loss. The UCI ADRC brings energetic and innovative multi-dimensional and multi- disciplinary approaches toward solving this insidious disease and also contributes to several national efforts.
The central goal of the University of California Alzheimer's Disease Research Center (UCI ADRC) is to conduct cutting-edge research that enables us to better understand Alzheimer's disease and to eventually translate discoveries into effective therapies, The UCI ADRC brings energetic and innovative multi-dimensional and multi-disciplinary approaches toward solving this insidious disease, contributes to several national collaborative efforts, and provides key resources to the research community here at UCI and elsewhere.
|Katsumata, Yuriko; Nelson, Peter T; Ellingson, Sally R et al. (2017) Gene-based association study of genes linked to hippocampal sclerosis of aging neuropathology: GRN, TMEM106B, ABCC9, and KCNMB2. Neurobiol Aging 53:193.e17-193.e25|
|Brenowitz, Willa D; Keene, C Dirk; Hawes, Stephen E et al. (2017) Alzheimer's disease neuropathologic change, Lewy body disease, and vascular brain injury in clinic- and community-based samples. Neurobiol Aging 53:83-92|
|Shelton, Lindsey B; Baker, Jeremy D; Zheng, Dali et al. (2017) Hsp90 activator Aha1 drives production of pathological tau aggregates. Proc Natl Acad Sci U S A 114:9707-9712|
|Moga, Daniela C; Abner, Erin L; Wu, Qishan et al. (2017) Bladder antimuscarinics and cognitive decline in elderly patients. Alzheimers Dement (N Y) 3:139-148|
|Stark, Shauna M; Reagh, Zachariah M; Yassa, Michael A et al. (2017) What's in a context? Cautions, limitations, and potential paths forward. Neurosci Lett :|
|Sennik, Simrin; Schweizer, Tom A; Fischer, Corinne E et al. (2017) Risk Factors and Pathological Substrates Associated with Agitation/Aggression in Alzheimer's Disease: A Preliminary Study using NACC Data. J Alzheimers Dis 55:1519-1528|
|Chang, Timothy S; Teng, Edmond; Elashoff, David et al. (2017) Optimizing Effect Sizes With Imaging Enrichment and Outcome Choices for Mild Alzheimer Disease Clinical Trials. Alzheimer Dis Assoc Disord 31:19-26|
|Abud, Edsel M; Ramirez, Ricardo N; Martinez, Eric S et al. (2017) iPSC-Derived Human Microglia-like Cells to Study Neurological Diseases. Neuron 94:278-293.e9|
|Kim, Julia; Schweizer, Tom A; Fischer, Corinne E et al. (2017) The Role of Cerebrovascular Disease on Cognitive and Functional Status and Psychosis in Severe Alzheimer's Disease. J Alzheimers Dis 55:381-389|
|Neu, Scott C; Pa, Judy; Kukull, Walter et al. (2017) Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis. JAMA Neurol 74:1178-1189|
Showing the most recent 10 out of 452 publications